002675.SHE Yantai Dongcheng Pharmaceutical Co Ltd
- Market cap
- CNY 10.5B
- P/E
- 49.2x
- P/B
- 2.37x
- ROE
- 4.9%
- Dividend yield
- 0.23%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002675.SHE undervalued?
Graham number002675.SHE trades 127.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Yantai Dongcheng Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Yantai Dongcheng Pharmaceutical Co Ltd yet.
Yantai Dongcheng Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Yantai Dongcheng Pharmaceutical Co Ltd
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. engages in the raw materials, formulations, nuclear medicine, and big health businesses in China and internationally. It operates through API, Formulation, Radio Pharmaceutical, and Others segments. The company offers formulation products, such as powder injections, tablets, capsules, granules, and drop pills for anticoagulation, cardiovascular, anti-tumor, urology, orthopedics, and anti-infection applications. It also provides …
Full company profileYantai Dongcheng Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Yantai Dongcheng Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.16B | 1.60B | 2.33B | 2.99B | 3.42B | 3.91B | 3.58B | 3.28B | 2.87B | 2.72B | 2.58B |
| Gross Profit | 545M | 868M | 1.33B | 1.77B | 1.66B | 1.59B | 1.53B | 1.35B | 1.35B | 1.30B | 1.36B |
| Operating Income | 240M | 314M | 468M | 394M | 609M | 357M | 448M | 342M | 221M | 352M | 441M |
| EBITDA | 263M | 416M | 587M | 750M | 728M | 728M | 672M | 512M | 433M | 572M | 423M |
| Net Income | 131M | 173M | 280M | 155M | 418M | 152M | 307M | 210M | 184M | 196M | 218M |
| EPS | 0.20 | 0.25 | 0.37 | 0.19 | 0.52 | 0.19 | 0.38 | 0.25 | 0.22 | 0.24 | 0.26 |
| Balance Sheet | |||||||||||
| Total Assets | 4.27B | 5.27B | 6.97B | 7.29B | 7.39B | 7.66B | 8.18B | 8.08B | 8.63B | 9.26B | 9.10B |
| Total Liabilities | 1.18B | 1.98B | 2.36B | 2.52B | 2.43B | 2.63B | 2.89B | 2.69B | 3.26B | 3.61B | 3.82B |
| Shareholders' Equity | 2.77B | 2.90B | 4.18B | 4.29B | 4.47B | 4.40B | 4.75B | 4.78B | 4.48B | 4.35B | 4.45B |
| Cash & Short-term Investments | 935M | 805M | 1.23B | 1.05B | 834M | 956M | 1.05B | 665M | 905M | 1.10B | 748M |
| Total Debt | 667M | 1.18B | 1.24B | 865M | 912M | 1.05B | 636M | 792M | 785M | 2.61B | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 196M | 209M | 493M | 696M | 573M | 944M | 997M | 277M | 287M | 585M | - |
| Capital Expenditure | 131M | 144M | 121M | 250M | 262M | 530M | 390M | 512M | 456M | 361M | 306M |
| Free Cash Flow | 65.1M | 65.0M | 372M | 446M | 310M | 413M | 607M | -235M | -169M | 224M | 35.6M |
| Ratios | |||||||||||
| ROE | 4.7% | 5.9% | 6.7% | 3.6% | 9.3% | 3.4% | 6.5% | 4.4% | 4.1% | 4.5% | 4.9% |
| ROA | 3.1% | 3.3% | 4.0% | 2.1% | 5.7% | 2.0% | 3.8% | 2.6% | 2.1% | 2.1% | 2.4% |
| Net Profit Margin | 11.3% | 10.8% | 12.0% | 5.2% | 12.2% | 3.9% | 8.6% | 6.4% | 6.4% | 7.2% | 8.5% |
| Debt to Equity | 0.24x | 0.41x | 0.30x | 0.20x | 0.20x | 0.24x | 0.13x | 0.17x | 0.18x | 0.60x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Yantai Dongcheng Pharmaceutical Co Ltd dividends
- Dividend yield
- 0.23%
- Forward dividend
- 0.08 CNY
- Payout ratio
- 12.6%
- Ex-dividend date
- Apr 29, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 24.7M | 0.03 | 12.6% |
| 2024 | CNY 217M | 0.26 | 118.2% |
| 2023 | CNY 258M | 0.31 | 123.2% |
| 2022 | CNY 251M | 0.31 | 81.8% |
| 2021 | CNY 302M | 0.38 | 199.6% |
| 2020 | CNY 348M | 0.43 | 83.2% |
| 2019 | CNY 247M | 0.31 | 159.3% |
| 2018 | CNY 133M | 0.18 | 47.4% |
| 2017 | CNY 84.4M | 0.12 | 48.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 30:10 on Aug 30, 2016.
Who owns Yantai Dongcheng Pharmaceutical Co Ltd
- Insiders 42.06%
- Institutions 4.30%
- Public & others 53.64%
- Shares outstanding 825M
- Free float 475M
Yantai Dongcheng Pharmaceutical Co Ltd company profile
- Company name
- Yantai Dongcheng Pharmaceutical Co Ltd
- Ticker
- 002675.SHE
- ISIN
- CNE100001DP5
- Exchange
- Shenzhen Stock Exchange
- Listed since
- May 25, 2012
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2,583
- Fiscal year end
- December
- Address
- No.7 Changbaishan Road, Yantai, China, 264006
- Phone
- 86 53 5639 1521
- Website
- dcb-group.com
About Yantai Dongcheng Pharmaceutical Co Ltd
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. engages in the raw materials, formulations, nuclear medicine, and big health businesses in China and internationally. It operates through API, Formulation, Radio Pharmaceutical, and Others segments. The company offers formulation products, such as powder injections, tablets, capsules, granules, and drop pills for anticoagulation, cardiovascular, anti-tumor, urology, orthopedics, and anti-infection applications. It also provides active pharmaceutical ingredients, including heparin, chondroitin sulfate sodium and calcium, hyaluronic acid, cytochrome C, and collagen, as well as glucosamine hydrochloride, glucosamine sulfate sodium chloride, and glucosamine sulfate potassium chloride; and nadroparin calcium for injection, hydrocortisone sodium succinate for injection, chorionic gonadotrophin for injection, menotropins for injection, ambroxol hydrochloride dispersible tablets, jinjunling capsules, metformin hydrochloride and glibenclamide tablets, clemastine fumarate tablets, and wind-dispelling itch-relieving granules. In addition, the company offers Technetium Methylene Diphosphonate injections; Technetium Tc=labeled tracers; 2-[18F]FDG for early diagnosis of tumors; sodium iodide oral solution; iodine seeds used for internal radiation treatment of various malignant tumors; urea capsules; and jiabaolin glucosamine chondroitin sulfate capsules. Further, it engages in trading; medical technology; medical devices; technical services; biotechnology service promotion; medical research and experimental development; business services; enterprise management, business information, and financial consulting; multimodal transport and transport agency services; capital market services; operation of local platforms for images; and engineering activities. The company exports its products to approximately 40 countries and regions. Yantai Dongcheng Pharmaceutical Group Co.,Ltd. was founded in 1998 and is headquartered in Yantai, China.
Yantai Dongcheng Pharmaceutical Co Ltd management
7- Mr. Zhi Gang LuoGM & Non-Independent Director · born 1970
- Ms. Chun Ping ZhuChief Financial Officer · born 1965
- Ms. Sai YouDeputy GM & Non-Independent Director · born 1986
- Mr. Xiao Jie LiuDeputy GM, Board Secretary & Director · born 1982
- Mr. Chun Xiang LuDeputy General Manager · born 1975
- Ms. Jing SunDeputy General Manager · born 1970
- Jing ZhouAccounting Supervisor